407
Participants
Start Date
March 31, 2010
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
ONO-4641
0.15 mg once per day for 26 weeks
ONO-4641
0.1 mg once per day for 26 weeks
ONO-4641
0.05 mg once per day for 26 weeks
ONO-4641 placebo
Placebo once per day for 26 weeks
La Louviere Clinical Site 201, La Louvière
Brugge Clinical Site 203, Bruges
Sijsele Clinical Site 202, Sijsele
Athens Clinical Site 243, Athens
Berlin Clinical Site 223, Berlin
Rochester Clinical Site 108, Rochester
Girona Clinical Site 254, Girona
Philadelphia Clinical Site 120, Philadelphia
Vinnytsya Clinical Site 342, Vinnytsia
HighPoint Clinical Site 128, HighPoint
Raleigh Clinical Site 103, Raleigh
Charlotte Clinical Site 125, Charlotte
Ormond Beach Clinical Site 129, Ormond Beach
Sarasota Clinical Site 116, Sarasota
Sarasota Clinical Site 117, Sarasota
Marburg Clinical Site 228, Marburg
Giessen Clinical Site 221, Giessen
Knoxville Clinical Site 134, Knoxville
Sevilla Clinical Site 256, Seville
Akron Clinical Site 112, Akron
Essen Clinical Site 222, Essen
Indianapolis Clinical Site 121, Indianapolis
Fort Wayne Clinical Site 111, Fort Wayne
Bilbao Clinical Site 255, Bilbao
Munster Clinical Site 225, Münster
Detroit Clinical Site 104, Detroit
Farmington Hills Clinical Site 126, Farmington Hills
Dnipropetrovsk Clinical Site 341, Dnipropetrovsk
Mainz Clinical Site 231, Mainz
Thessaloniki Clinical Site 245, Thessaloniki
Northbrook Clinical Site 135, Northbrook
Kharkiv Clinical Site 346, Kharkiv
Tubingen Clinical Site 226, Tübingen
Round Rock Clinical Site 107, Round Rock
Lviv Clinical Site 343, Lviv
Aurora Clinical Site 132, Aurora
Fort Collins Clinical Site 123, Fort Collins
Tucson Clinical Site 133, Tucson
Albuquerque Clinical Site 106, Albuquerque
Ulm Clinical Site 230, Ulm
Seattle Clinical Site 118, Seattle
Moscow Clinical Site 332, Moscow
Yaroslavl Clinical Site 331, Yaroslavl
Kazan Clinical Site 333, Kazan'
Kaluga Clinical Site 328, Kaluga
St. Petersburg Clinical Site 325, Saint Petersburg
St. Petersburg Clinical Site 327, Saint Petersburg
Samara Clinical Site 328, Samara
Ufa Clinical Site 326, Ufa
Chelyabinsk Clinical Site 322, Chelyabinsk
Nizhniy Novgorod Clinical Site 321, Nizhny Novgorod
Novosibirsk Clinical Site 324, Novosibirsk
Fairfield Clinical Site 110, Fairfield
Lebanon Clinical Site 115, Lebanon
Gatineau Clinical Site 114, Gatineau
Kanto Region Clinical Site 404, Kanto
Kanto Region Clinical Site 405, Kanto
Kanto Region Clinical Site 406, Kanto
Kanto Region Clinical Site 409, Kanto
Kinki Region Clinical Site 401, Kinki
Kinki Region Clinical Site 407, Kinki
Kinki Region Clinical Site 408, Kinki
Tohoku Region Clinical Site 403, Tōhoku
Tohoku Region Clinical Site 410, Tōhoku
Greenfield Park Clinical Site 109, Greenfield Park
Vancouver Clinical Site 131, British Columbia
Montreal Clinical Site 113, Québec
Montreal Clinical Site 102, Québec
Olomouc Clinical Site 212, Olomouc
Ostrava Clinical Site 214, Ostrava
Pardubice Clinical Site 211, Pardubice
Praha 5 Clinical Site 213, Prague
Leipzig Clinical Site 229, Leipzig
Bialystok Clinical Site 305, Bialystok
Czeladz Clinical Site 303, Czeladź
Gdansk Clinical Site 302, Gdansk
Katowice Clinical Site 309, Katowice
Krakow Clinical Site 307, Krakow
Lodz Clinical Site 306, Lodz
Plewiska Clinical Site 304, Plewiska
Warszawa Clinical Site 308, Warsaw
Barcelona Clinical Site 252, Barcelona
Barcelona Clinical Site 253, Barcelona
Hospitalet de Llobregat Clinical Site 251, L'Hospitalet de Llobregat
Donetsk Clinical Site 345, Donetsk
Kyiv Clinical Site 344, Kyiv
Lead Sponsor
Ono Pharma USA Inc
INDUSTRY